μ阿片受体激动剂研究进展
Research Progress of μ-Opioid Receptor Agonist
作者: 舒 浪 , 田崎峰 ：武汉工程大学化工与制药学院，湖北 武汉; 邵开元 , 胡文祥 ：北京神剑天军医学科学院，北京;
关键词: 阿片受体； 镇痛药； μ受体激动剂； 内吗啡肽； Opioid Receptor； Analgesics； μ-Opioid Receptor Agonist； Endomorphins
摘要:Abstract: In the 1960s, the discovery of new analgesic fentanyl caused the boom of new analgesic study around the world; people began to study pharmacological effects, biological activity and other characters of the new analgesic of morphine and fentanyl, which is similar to morphine on structure. Since the 1970s, the existence of opioid receptors and endogenous opioid peptides has been found in the brain; many scholars have begun to study the structure of opioid receptor actively. There are mainly three types of opioid receptors (μ, δ, κ), and wherein, μ receptor protein is the primary receptor site of morphine, fentanyl and other analgesics. Following the discovery of fentanyl, many other highly active fentanyl analogs have been found, such as Ohmefentanyl (OMF). Recently, many studies have shown that gene knock-out of δ-opioid receptor or antagonists can reduce or suppress tolerance and drug dependency—the side effects of μ-opioid analgesics for long-term administration.
文章引用: 舒 浪 , 田崎峰 , 邵开元 , 胡文祥 (2015) μ阿片受体激动剂研究进展。 有机化学研究， 3， 44-50. doi: 10.12677/JOCR.2015.31006
参考文献
[1] Janssen, P.A.J. (1962) A review of the chemical features associated with strong morphine-like activity. British Journal of Anaesthesia, 34, 260.
[2] 孔令锁, 胡宪文, 张野 (2011) 阿片受体激动剂预处理对器官缺血/再灌注损伤的保护作用. 国际麻醉学与复苏杂志, 5, 600-603.
[3] Evans, C.J., Keith, D.E., Morison, H., et al. (1992) Cloning of a delta opioid receptor by functional expression. Science, 258, 1952-1955.
[4] Chen, Y., Mestek, A., Yu, L., et al. (1993) Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Molecular Pharmacology, 44, 8-12.
[5] 池志强 (1998) 阿片受体研究最新进展. 生命科学, 2, 90-93.
[6] 晏庭林, 李琳, 刘新社 (2009) 阿片受体及阿片肽研究进展. 中国药物依赖性杂志, 5, 375-379.
[7] Andersen, G. (2003) Relationships among morphine metabolism, pain and side effects during long-term treatment, an update. Journal of Pain and Symptom Management, 25, 74-91.
[8] Zadina, J.E. and Martin-Schild, S. (1999) Endomorphins, novel endogenous μ-opiate receptor agonists in regions of high μ-opiate receptor density. Annals New York Academy of Sciences, 897,136-144.
[9] Zadina, J.E., Hackler, L. and Ge, L.J. (1997) A potent and selective endogenous agonist for the μ-opiate receptor. Nature, 386, 499-502.
[10] 任维华, 霍笑风, 吴宁 (2001) 内吗啡肽研究进展. 中国药理学通报, 1, 17-20.
[11] Liu, X., Wang, Y., Xing, Y.H., Yu, J., Ji, H., Kai, M., et al. (2013) Design, synthesis, and pharmaco-logical characterization of novel endomorphin-1 analogues as extremely potent μ-opioid agonists. Journal of Medicinal Chemistry, 56, 3102-3114.
[12] Narita, M., Ozaki, S. and Suzuki, T. (2002) Endomorphin-induced motivational effect: Differential mechanism of endomorphin-1 and endomorphin-2. Japanese Journal of Pharmacology, 89, 224-228.
[13] Horvath, G. (2000) Endomorphin-1 and endomorphin-2: Pharmacology of the selective endogenous μ-opioid receptor agonists. Pharmacology & Therapeutics, 88, 437-463.
[14] 李玉林, 徐筱杰 (1989) 芬太尼类化合物与阿片受体相互作用的构象分析. 物理化学学报, 6, 681-687.
[15] Yekkirala, A.S., Banks, M.L., Lunzer, M.M., Negus, S.S., Rice, K.C. and Portoghese, P.S. (2012) Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in rhesus monkeys. ACS Chemical Neuroscience, 3, 720-727.
[16] Weltrowska, G., Chung, N.N., Lemieux, C., et al. (2010) “Carba”-analogues of fentanyl are opioid receptor agonists. Journal of Medicinal Chemistry, 53, 2875-2881.
[17] 温素妲, 杨玉龙, 邵华宙, 张开镐, 李玉林, 陈冀胜 (1993) 4-甲氧羰基芬太尼非芳基类似物的合成及镇痛作用. 药学学报, 3, 181-187.
[18] 徐珩, 陈浩, 池志强 (1984) 羟甲芬太尼(Ohmefentanyl), 一个新的μ阿片受体激动剂. 中国科学, 8, 733-739.
[19] 池志强, 朱友成, 金文桥, 徐珩, 周德和, 叶淑珍 (1999) 羟甲芬太尼——一种新型的高选择性μ阿片受体激动剂. 中国科学基金, 4, 280-283.
[20] Healy, J.R., Bezawada, P., Shim, J., Jones, J.W., Kane, M.A., MacKerell, A.D., et al. (2013) Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ-agonist/δ-antagonist opioid analgesic with reduced tolerance liabilities. ACS Chemical Neuroscience, 4, 1256-1266.
[21] Balboni, G., Salvadori, S., Trapella, C., et al. (2010) Evolution of the bifunctional lead μ agonist/δ antagonist containing the 2’,6’-dimethyl-L-tyrosine-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Dmt-Tic) opioid pharmacophore. ACS Chemical Neuroscience, 1, 155-164.
[22] 胡文祥, 刘明 (2014) 阿片受体分子药学. 化学工业出版社, 北京.